The two-year, full-time MS/MBA Biotechnology: Life Sciences program will begin in August 2020, with a highly selective first-year cohort of just seven to 10 students. The curriculum will prepare students to develop health-focused organizations based on science and medicine, with an emphasis on building effective structures for biotech discovery and development, and the ethical implications and equitable access thereof.
“The world needs more leaders able to bridge science and business,” said Nitin Nohria, PhD, dean of Harvard Business School. “We aim to provide graduates of this new program with tools to understand the most modern biomedical science issues, as well as knowledge of scientific methodologies and timeframes, so they can be effective leaders in this domain.”
The Master of Science component will be led by Harvard scientists and clinicians with experience in biotechnology and pharmaceuticals, while Master of Business Administration classes will be taught by experts in biotech leadership, financing and social implications.
More articles on integration and physician issues:
HHS awards $20M to bolster rural residency programs
Salary potential influences most residency choices: 10 highest-paid residencies
Study: Pharmacists can reduce primary care provider burnout
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.